Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors

Journal of Medicinal Chemistry

Volumn 40, Issue 13, 1997, Pages 1955-1968

  Stewart, Andrew O ^a   Bhatia, Pramila A ^a   Martin, Jonathan G ^a   Summers, James B ^a   Rodriques, Karen E ^a   Martin, Michael B ^a   Holms, James H ^a   Moore, Jimmie L ^a   Craig, Richard A ^a   Kolasa, Teodozyj ^a   Ratajczyk, James D ^a   Mazdiyasni, Hormoz ^a   Kerdesky, Francis A J ^a   DeNinno, Shari L ^a   Maki, Robert G ^a   Bouska, Jennifer B ^a   Young, Patrick R ^a   Lanni, Carmine ^a   Bell, Randy L ^a   Carter, George W ^a   Brooks, Clint D W ^a   more..

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; HYDROXYUREA; LIPOXYGENASE INHIBITOR; N [3 [5 (4 FLUOROPHENOXY) 2 FURYL] 1 METHYL 2 PROPYNYL] N HYDROXYUREA; UNCLASSIFIED DRUG;

ARTICLE; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; GLUCURONIDATION; LIPOPHILICITY; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CELLS, CULTURED; DRUG DESIGN; ENZYME INHIBITORS; FURANS; GLUCURONATES; HUMANS; HYDROXYUREA; MACACA FASCICULARIS; MODELS, CHEMICAL; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TEMPLATES, GENETIC; THIOPHENES;

EID: 15144342082     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9700474     Document Type: Article

References (43)

1. (a) Israel, E. Moderating the inflammation of asthma: inhibiting the production or action of products of the 5-lipoxygenase pathway. Ann. Allergy 1994, 72, 279-284.
2. (b) Brooks, D. W. Progress with investigational drugs for the treatment of pulmonary and inflammatory diseases. Expert Opin. Invest. Drugs 1994, 3, 185-190.
3. Samuelsson, B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983, 220, 568-575.
4. (a) Corey, E. J.; Niwa, H.; Falck, J. R.; Mioskowski, C.; Arai, Y.; Marfat, A. Recent studies on the chemical synthesis of eicosanoids. Adv. Prostaglandin Thromboxane Res. 1980, 6, 19-25.
5. (b) Borgeat, P.; Sirois, P. Leukotrienes: a major step in understanding immediate hypersensitivity reactions. J. Med. Chem. 1981, 24, 121-126.
6. Brooks, C. D. W.; Summers, J. B. Modulators of Lekotriene Biosynthesis and Receptor Activation. J. Med. Chem. 1996, 39, 2629-2654.
7. (a) Rouzer, C. A.; Samuelsson, B. Leukocyte arachidonate 5-lipoxygenase isolation and characterization. Methods Enzymol. 1990, 187, 312-319.
8. (b) Steinhilber, D. 5-Lipoxygenase: enzyme expression and regulation of activity. Pharm. Acta Helv. 1994, 69, 3-14.
9. (c) Radmark, O. Arachidonate 5-lipoxygenase. J. Lipid Med. Cell Signalling 1995, 12, 171-184.
10. Percival, M. D. Human 5-lipoxygenase contains an essential iron. J. Biol. Chem. 1991, 266, 10058-10061.
11. (a) Musser, J. H.; Kreft, A. F. 5-Lipoxygenase: properties, pharmacology and the quinolinyl(bridged)aryl class of inhibitors. J. Med. Chem. 1992, 35, 2502-2524.
12. (b) Garland, L. G.; Salmon, J. A. Hydroxamic acids and hydroxyureas as inhibitors of arachidonate 5-lipoxygenase. Drugs Future 1991, 16, 547-558.
13. (c) Batt, D. G. 5-Lipoxygenase inhibitors and their anti-inflammatory activities. In Progress in Medicinal Chemistry; Ellis, G. P., Luscombe, D. K., Eds.; Elsevier Science Publishers: New York, 1992; Vol. 29, pp 1-63.
14. (d) McMillan, R. M.; Walker, E. R. H. Designing therapeutically effective 5-lipoxygenase inhibitors. Trends Pharmacol. Sci. 1992, 13, 323-330.
15. Corey, E. J.; Cashman, J. R.; Kanter, S. S.; Corey, D. R. Rationally designed, potent competitive inhibitors of leukotriene biosynthesis. J. Am. Chem. Soc. 1984, 106, 1503-1504.
16. Summers, J. B.; Gunn, B. P.; Mazdiyasni, H.; Goetze, A. M.; Young, P. R.; Bouska, J. B.; Dyer, R. D.; Brooks, D. W.; Carter, G. W. In vivo characterization of hydroxamic acid inhibitor of 5-lipoxygenase. J. Med. Chem. 1987, 30, 2121-2126.
17. (a) Summers, J. B.; Gunn, B. P.; Martin, J. G.; Mazdiyasni, H.; Stewart, A. O.; Young, P. R.; Goetze, A. M.; Bouska, J. B.; Dyer, R. D.; Brooks, D. W.; Carter, G. W. Orally active hydroxamic acid inhibitors of leukotriene biosynthesis. J. Med. Chem. 1988, 31, 3-5.
18. (b) Summers, J. B.; Gunn, B. P.; Martin, J. G.; Martin, M. B.; Mazdiyasni, H.; Stewart, A. O.; Young, P. R.; Bouska, J. B.; Goetze, A. M.; Dyer, R. D.; Brooks, D. W.; Carter, G. W. Structure-activity analysis of a class of orally active hydroxamic acid inhibitors of leukotriene biosynthesis. J. Med. Chem. 1988, 31, 1960-1964
19. (a) Summers, J. B.; Gunn, B. P.; Brooks, D. W. Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds. U.S. Patent 4873259, Oct. 10, 1989.
20. (b) Carter, G. W.; Young, P. R.; Albert, D. H.; Bouska, J.; Dyer, R. D.; Bell, R. L.; Summers, J. B.; Brooks, D. W.; Gunn, B. P.; Rubin, P.; Kesterson, J. A-64077, a new orally active 5-lipoxygenase inhibitor. In Leukotrienes and Prostanoids in Health and Disease, New Trends in Lipid Mediators Research; Zor, U., Naor, Z., Danon, A., Eds.; Karger: Basel, 1989; pp 50-55.
21. (c) Brooks, D. W.; Summers, J. B.; Gunn, B. P.; Rodriques, K. E.; Martin, J. G.; Martin, M. B.; Mazdiyasni, H.; Holms, J. H.; Stewart, A. O.; Moore, J. L.; Young, P. R.; Albert, D. H.; Bouska, J. B.; Malo, P. E.; Dyer, R. D.; Bell, R. L.; Rubin, P.; Kesterson, J.; Carter, G. W. The discovery of A-64077, a clinical candidate for treating diseases involving leukotriene mediators. Abstracts of the International Chemical Congress of Pacific Basin Societies, Honolulu, 1989, Abstract BIOS 34.
22. (d) Carter, G. W.; Young, P. R.; Albert, D. H.; Bouska, J.; Dyer, R.; Bell, R. L.; Summers, J. B.; Brooks, D. W. 5-Lipoxygenase inhibitory activity of zileuton. J. Pharmacol. Exp. Ther. 1991, 256, 929-937.
23. Brooks, D. W.; Carter, G. W. The discovery of zileuton. In The Search for Anti-Inflammatory Drugs; Merluzzi, V. J., Adams, J., Eds.; Birkhauser: Boston, 1995; Chapter 5, pp 129-160.
24. (a) Rubin, P.; Dubé, L.; Braeckman, R.; Swanson, L.; Hanson, R.; Albert, D.; Carter, G. Pharmacokinetics, safety and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase. In Progress in Inflammation, Research and Therapy; Ackerman, N. R., Bonney, R. J., Welton, A. F., Eds.; Birkhauser: Basel, 1991; pp 103-116.
25. (b) Braeckman, R. A.; Granneman, R.; Rubin, P. R.; Kesterson, J. W. Pharmacokinetics and metabolism of the new 5-lipoxygenase inhibitor A-64077 after single oral administration in man. J. Clin. Pharmacol. 1989, 29, 837.
26. Israel, E.; Rubin, P.; Kemp, J. P.; Grossman, J.; Pierson, W.; Siegel, S. C.; Tinkelman, D.; Murray, J. J.; Busse, W.; Segal, A. T.; Fish, J.; Kaiser, H. B.; Ledford, D.; Wenzel, S.; Rosenthal, R.; Cohn, J.; Lanni, C.; Perlman, H.; Karahalios, P.; Drasen, J. M. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann. Intern. Med. 1993, 119, 1059-1066.
27. Kawase, M.; Kikugawa, Y. Chemistry of Amine-Boranes. Part 5. Reduction of Oximes, O-Acyl-oximes, and O-Alkyl-oximes with Pyridine-Borane in Acid. J. Chem. Soc., Perkin 1 Trans. 1979, 643-645.
28. Borch, R. F.; Bernstien, M. D.; Dupont Durst, H. The Cyanohydridoborate Anion as a Selective Reducing Agent. J. Am. Chem. Soc. 1971, 93, 2897-2904.
29. Rodriques, K. E.; Basha, A.; Summers, J. B.; Brooks, D. W. Addition of Aryllithium Compounds to Oxime Ethers. Tetrahedron Lett. 1988, 29, 3455-3458.
30. Uno, H.; Terakawa, T.; Suzuki, H. Boron Trifluoride Promoted Addition of Organolithiums to Oxime Ethers. A Facile Synthesis of Substituted Hydroxylamines. Synlett 1991, 559-560.
31. Basha, A.; Ratajczyk, J. D.; Brooks, D. W. Addition Of Organolithium Compounds To N-THP Protected Nitrones. Tetrahedron Lett. 1991, 32, 3783-3786.
32. Goto, G.; Kawakita, K.; Okutani, T.; Miki, T. An Improved Synthesis of N-hydroxyamino Acids and Thier Esters Using (Z)-2-Furaldehyde Oxime. Chem. Pharm. Bull. 1986, 34, 3202-3207.
33. Lee, B. H.; Miller, M. J. Natural Ferric Ionophores: Total Synthesis of Schizokinen, Schizokinen A, and Arthrobactin. J. Org. Chem. 1983, 48, 24-31.
34. Stewart, A. O.; Brooks, D. W. N,O-Bis(phenoxycarbonyl)hydroxylamine: a new reagent for the direct synthesis of substituted N-hydroxyureas. J. Org. Chem. 1992, 57, 5020-5023.
35. Brooks, C. D. W.; Stewart, A. O.; Basha, A.; Bhatia, P.; Ratajczyk, J. D.; Martin, J. G.; Craig, R. A.; Kolasa, T.; Bouska, J. B.; Lanni, C.; Harris, R. R.; Malo, P. E.; Carter, G. W.; Bell, R. L. (R)-(+)-N-[3-[5(4-Fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N- hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor. J. Med. Chem. 1995, 38, 4768-4775.
36. Trost, B. M.; Belletire, J. L.; Godleski, S.; McDougal, P. G.; J. M. Balkovec, J. M.; Baldwin, J. J.; Christy, M. E.; Ponticello, G. S.; Varaga, S. L.; Springer, J. P. On the Use of the O-Methylmandelate Ester for Establishment of Absolute Configuration of Secondary Alcohols. J. Org. Chem. 1986, 51, 2370-2374
37. Young, P. R.; Bell, R. L.; Lanni, C.; Summers, J. B.; Brooks, D. W.; Carter, G. W. Inhibition of leukotriene biosynthesis in the rat peritoneal cavity. Eur. J. Pharmacol. 1991, 205, 259-266.
38. Ohemeng, K. A.; Appollina, M. A.; Nguyen, V. N.; Schwender, C. F.; Singer, M.; Steber, S.; Ansell, J.; Argentieri, D.; Hageman, W. Synthesis and 5-lipoxygenase Inhibitory Activities of Some Novel 2-Substituted 5-Benzofuran Hydroxamic Acids. J. Med. Chem. 1994, 37, 3663-3667.
39. Jackson, W. P.; Islip, P. J.; Kneen, G.; Pugh, A.; Wates, P. J. Acetohydroxamic Acids as Potent, Selective, Orally Active 5-Lipoxygenase Inhibitors. J. Med. Chem. 1988, 31, 499-500.
40. Bell, R. L.; Lanni, C.; Malo, P. E.; Brooks, D. W.; Stewart, A. O.; Hansen, R.; Rubin, P.; Carter, G. W. Preclinical and Clinical Activity of Zileuton and A-78773. Ann. N.Y. Acad. Sci. 1993c, 696, 205-215.
41. Bell, R. L.; Bouska, J. B.; Malo, P. E.; Lanni, C.; Harris, R. R.; Otis, E. R.; Stewart, A. O.; Brooks, D. W.; Carter, G. W. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors. J. Pharmacol. Exp. Ther. 1995, 272, 724-731.
42. Frankel, M.; Knobler, M.; Bonni, E.; Bittner, S.; Zvilichovsky, G. DL-Cycloanaline (Cyclohomoserine) and Related Compounds. J. Chem. Soc C 1969, 1746-1749.
43. Klemm, L. H.; Klopfenstein, C. E.; Zell, R.; McCoy, D. R.; Klemm, R. A. Chemistry of Thienopyridines. III. Syntheses of Thieno-[2,3-b]- and Thieno[3,2-b]pyridine Systems. Direct Substitution into the Former System. J. Org. Chem. 1969, 34, 347-354.